Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Investing Activities (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Cash from Investing Activities for 6 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 1630.48% year-over-year to $5.1 million, compared with a TTM value of $43.5 million through Sep 2025, up 385.92%, and an annual FY2024 reading of $54.6 million, up 2215.23% over the prior year.
  • Cash from Investing Activities was $5.1 million for Q3 2025 at Ovid Therapeutics, down from $12.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $30.2 million in Q1 2023 and bottomed at -$80.7 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is -$814927.2, with a median of -$11514.0 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities plummeted 9246.58% in 2022, then surged 2908.96% in 2023.
  • Year by year, Cash from Investing Activities stood at -$161958.0 in 2021, then crashed by 2474.44% to -$4.2 million in 2022, then crashed by 1063.59% to -$48.5 million in 2023, then soared by 143.89% to $21.3 million in 2024, then plummeted by 76.27% to $5.1 million in 2025.
  • Business Quant data shows Cash from Investing Activities for OVID at $5.1 million in Q3 2025, $12.1 million in Q2 2025, and $5.1 million in Q1 2025.